Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

The FDA has scuttled Merus’ plans to win a speedy approval for i | The FDA has scuttled Merus’ plans to win a speedy approval ...

Sana Biotechnology has become the latest cell therapy biotech to shift resources from cancer to autoimmune diseases as part of a ...

Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies. | Cellectis has deprioritized one of its leukemia-focused ...

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the ...

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Swiss biotech Relief Therapeutics is slated to enter a reverse merger with private U.S. biotech Renexxion and forge ahead ...

| While artificial intelligence is on everyone’s minds and in many R&D plans, adoption of generative AI has been slow so far ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.